Login/Sign Up
Natlimus 0.5 mg Tablet 10's
₹1282.5*
MRP ₹1425
10% off
₹1211*
MRP ₹1425
15% CB
₹214 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Whats That
Natlimus 0.5 mg Tablet belongs to the group of medicine called ‘anti-cancer’. It is primarily used to treat breast cancer, pancreatic cancer, lung cancer and kidney cancer. Breast cancer is a type of cancer that develops in breast cells stimulated by the female sex hormone known as estrogen. Pancreatic cancer is described as a cancerous growth in the pancreas which normally begins in the cells that generate the juices that help break down food and the hormones which help in controlling blood sugar levels. Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs.
Natlimus 0.5 mg Tablet contains 'Everolimus' which belongs to the group of medicines known as 'kinase inhibitors'. It works by decreases the activity of the immune system of the body and prevents rejection of the transplanted organ. It works by stopping the action of an abnormal protein that causes the multiplication of cancerous cells. In this way, it stops the spread of cancerous cells.
Take Natlimus 0.5 mg Tablet as prescribed by your doctor. You are advised to take Natlimus 0.5 mg Tablet for as long as your doctor has prescribed it for you depending on your medical conditions. You may experience weakness, infection, sinus inflammation, cough, diarrhea, fever, fatigue, otitis media (infection of the ear), stomatitis (Inflammation of the mouth) and upper respiratory tract infection. Most of these side effects of Natlimus 0.5 mg Tablet do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.
To treat your condition effectually, continue taking Natlimus 0.5 mg Tablet for as long as your doctor has prescribed. If you are known to be allergic to Natlimus 0.5 mg Tablet or any other medicines, please tell your doctor. Do not take Natlimus 0.5 mg Tablet if you are pregnant or planning for pregnancy as Natlimus 0.5 mg Tablet may harm the unborn baby. Natlimus 0.5 mg Tablet should not be taken by breastfeeding mothers as it may cause harm to the newborn baby. Natlimus 0.5 mg Tablet causes tiredness, thus, it is advisable not to drive unless you are alert. Elderly people are more sensitive to medicine so they may adjust the dosage according to their condition.
Natlimus 0.5 mg Tablet is indicated to the patients dealing with breast cancer, pancreatic cancer, lung cancer, kidney cancer and stomach/ intestinal cancer. Cancer of this type tends to spread quickly in other parts of the body. Natlimus 0.5 mg Tablet travels through the bloodstream and effectively destroys cancerous cells and other parts of the body. It works by decreases the activity of the immune system of the body and prevents rejection of the transplanted organ. It works by stopping the action of an abnormal protein that causes the multiplication of cancerous cells. In this way, it stops the spread of cancerous cells. Besides this, it is also effective in people with genetic disorders to treat some types of tumors in the brain or kidney.
If you are known to be allergic to Natlimus 0.5 mg Tablet or any other medicines, please tell your doctor. Natlimus 0.5 mg Tablet should not be taken in the conditions like liver disease, diabetes and high level of cholesterol. Do not take Natlimus 0.5 mg Tablet if you have recent surgery, infection and hepatitis B. Natlimus 0.5 mg Tablet may weaken your immune system, inform your doctor before taking Natlimus 0.5 mg Tablet . Natlimus 0.5 mg Tablet may also impair your kidney function. Therefore, monitor your kidney function regularly while taking Natlimus 0.5 mg Tablet . Natlimus 0.5 mg Tablet may cause cough, fever and shortness of breathing, thereby inform your doctor while taking your Natlimus 0.5 mg Tablet . Natlimus 0.5 mg Tablet may cause skin cancer, if you observe night sweating, weight loss, or change in color and size of the mole inform your doctor. Do not take Natlimus 0.5 mg Tablet if you are pregnant or planning for pregnancy as Natlimus 0.5 mg Tablet may harm the unborn baby. Natlimus 0.5 mg Tablet should not be taken by breastfeeding mothers as it may cause harm to the newborn baby. Natlimus 0.5 mg Tablet causes tiredness, thus, it is advisable not to drive unless you are alert. Elderly people are more sensitive to medicine so they may adjust the dosage according to their condition.
Drug-Drug Interaction: Natlimus 0.5 mg Tablet may have interaction with antifungal medicines (ketoconazole, itraconazole, voriconazole, fluconazole), antibiotics (clarithromycin, telithromycin, erythromycin), anti-HIV medicines (ritonavir, efavirenz), blood pressure-lowering medicines (ramipril, verapamil, diltiazem), medicines for heart disease (dronedarone), medicines for decreasing growth of abnormal cells (imatinib), medicines for fits/ epilepsy (phenytoin, carbamazepine, phenobarbital).
Drug-Food Interaction: Avoid grapefruits and grapefruit juice.
Drug-Disease Interaction: Natlimus 0.5 mg Tablet should not be given to the patients with liver disease, kidney disease, diabetes, high level of cholesterol and infections.
Breast cancer: It is a type of cancer that develops in breast cells that are stimulated by a female sex hormone called estrogen. Breast cancer may form in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), in the fatty tissue or the fibrous connective tissue within the breast. The tumor cells invade other healthy breast cells and can travel to lymph nodes which are a primary pathway for the cancer cells to move to other parts of the body.
Lung cancer: It happens when cells in the lung begin to grow in an uncontrolled manner. The most common form of lung cancer is non-small cell lung cancer (NSCLC). It happens when cells that form the lining of the lung start growing uncontrollably. Persons who smoke are at high risk of lung cancer. A common symptom of lung cancer is a cough that does not go easily followed by shortness of breath. Cancerous cells of the lung spread off and travel through the bloodstream to distant regions of the body and grow.
Pancreatic cancer: It is described as a cancerous growth in the pancreas which normally begins in the cells that generate the juices. Juices are produced by the pancreas ( a gland present behind your stomach) help in the breakdown of food and hormones which help in controlling blood sugar levels.
Kidney cancer: Kidneys are the organs on either side of your backbone directly above your waist. The tubes present inside clean and filter your blood, taking out waste foods and making urine. Kidney cancer produces in the lining of tiny tubes inside your kidneys.
Alcohol
Caution
You are recommended to avoid alcohol consumption while taking Natlimus 0.5 mg Tablet to avoid unpleasant side-effects.
Pregnancy
Unsafe
Natlimus 0.5 mg Tablet is belonging to pregnancy C category. It is not safe in pregnancy as it may causes harm to the unborn baby. Do not conceive a baby while taking Natlimus 0.5 mg Tablet .
Breast Feeding
Unsafe
Natlimus 0.5 mg Tablet should not be taken by breastfeeding mothers as it may harm to the new-born baby.
Driving
Caution
Natlimus 0.5 mg Tablet may cause tiredness (fatigue), do not drive or operate heavy machinery if you feel dizzy.
Liver
Caution
Natlimus 0.5 mg Tablet should be taken with caution in patients dealing with liver disease. The doctor may adjust the dose according to the medical condition of the patient.
Kidney
Caution
Natlimus 0.5 mg Tablet is likely unsafe in patients with severe kidney disease as it may cause kidney failure which can be dangerous, use Natlimus 0.5 mg Tablet only when prescribed by a doctor.
Children
Unsafe
Natlimus 0.5 mg Tablet is not recommended for children below 18 years as the safety and effectiveness were not established.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes